Free tool
FAERS Monitor: Harliku
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209449 or its brand name (Harliku, Nitisinone). Reports on generic versions are filed under their own applications.
Reports
287
Serious
178
62% of reports
Hospitalization
67
Death reported
35
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- liver transplant33
- off label use32
- hepatocellular carcinoma22
- amino acid level increased20
- product dose omission issue16
- treatment noncompliance16
- death14
- hepatic failure13
- hepatic cirrhosis12
- hospitalisation12
- alpha 1 foetoprotein increased10
- drug ineffective10
- vitiligo9
- pruritus8
- rash8
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 9 |
| 2013 | 5 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 6 |
| 2019 | 18 |
| 2020 | 33 |
| 2021 | 44 |
| 2022 | 42 |
| 2023 | 39 |
| 2024 | 34 |
| 2025 | 31 |
| 2026 | 14 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,872 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| amino acid level increasedSignal | 20 | 2029.3 | 1321.4 | 37,506 |
| alpha 1 foetoprotein increasedSignal | 10 | 1045.0 | 565.9 | 9,280 |
| liver transplantSignal | 33 | 671.3 | 486.2 | 21,232 |
| vitiligoSignal | 9 | 282.3 | 148.2 | 2,241 |
| hepatocellular carcinomaSignal | 22 | 212.6 | 142.2 | 4,414 |
| hepatic cirrhosisSignal | 12 | 46.9 | 26.9 | 494 |
| hepatic failureSignal | 13 | 31.6 | 18.6 | 356 |
| treatment noncomplianceSignal | 16 | 21.4 | 13.3 | 292 |
| hospitalisationSignal | 12 | 5.7 | 3.3 | 42 |
| product dose omission issueSignal | 16 | 4.0 | 2.5 | 33 |
| off label useSignal | 32 | 2.7 | 1.9 | 33 |
| pruritus | 8 | 1.5 | 0.8 | 1 |
| rash | 8 | 1.3 | 0.7 | 0 |
| death | 14 | 1.2 | 0.7 | 0 |
| drug ineffective | 10 | 0.6 | 0.3 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.